参芪养心汤联合沙库巴曲缬沙坦治疗老年慢性心力衰竭的疗效及对患者血清趋化素与过氧化物酶体增殖物激活受体α水平的影响
Therapeutic Effect of Shenqi Yangxin Tang combined with Shakubaqu Valsartan on Elderly Chronic Heart Failure and Its Effects on Serum Chemokines and Peroxisome Proliferator-activated Receptors-α in Patients
林以 1肖长江2
作者信息
- 1. 湖南中医药大学研究生院,长沙 410000
- 2. 湖南省中医药研究院附属医院心内科,长沙 410000
- 折叠
摘要
目的 探讨参芪养心汤联合沙库巴曲缬沙坦治疗老年慢性心力衰竭(CHF)的疗效及对患者血清趋化素、过氧化物酶体增殖物激活受体α(PPAR-α)水平的影响.方法 选取 2021 年 3 月至 2023 年 3 月湖南省中医药研究院附属医院收治的老年CHF患者82 例作为研究对象,随机分为对照组和观察组,每组41 例.对照组采用沙库巴曲缬沙坦治疗,观察组联合参芪养心汤治疗,比较两组的治疗效果.结果 观察组治疗有效率高于对照组,差异有统计学意义(P＜0.05);治疗后,观察组左室射血分数(LVEF)水平高于对照组,左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)水平低于对照组,差异有统计学意义(P＜0.05);治疗后,观察组血清趋化素水平低于对照组,PPAR-α水平高于对照组,差异有统计学意义(P＜0.05);两组不良反应发生率比较差异无统计学意义(P＞0.05).结论 参芪养心汤联合沙库巴曲缬沙坦治疗老年CHF能有效改善心功能,调节血清趋化素、PPAR-α水平,疗效显著.
Abstract
Objective To explore the therapeutic effect of Shenqi Yangxin Tang combined with Shakubatra valisartan on elderly chronic heart failure(CHF)and its effect on serum chemokines and peroxisome proliferator-activated receptors-α(PPAR-α)in patients.Methods A total of 82 elderly CHF patients admitted to the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine from March 2021 to March 2023 were selected as the study objects and randomly divided into control group and observation group,with 41 cases in each group.The control group was treated with Sakubactril and valsartan,and the observation group was treated with Shenqi Yangxin Decoction.The therapeutic effect of the two groups was compared.Results The effective rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P＜0.05).After treatment,the level of left ventricular ejection fraction(LVEF)in observation group was higher than control group,the level of left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower than control group,the difference was statistically significant(P＜0.05).After treatment,the serum chemokine level in observation group was lower than that in control group,and the level of PPAR-α was higher than that in control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of Shenqi Yangxin Tang and Shakubaqu Valsartan in the treatment of elderly CHF can effectively improve cardiac function,regulate serum chemokines,and PPAR-α Level,significant therapeutic effect.
关键词
老年慢性心力衰竭/沙库巴曲缬沙坦/参芪养心汤/过氧化物酶体增殖物激活受体-α/血清趋化素Key words
Elderly chronic heart failure/Shakubaqu valsartan/Shenqi Yangxin Tang/Peroxisome proliferator activated receptor-α/Serum chemotactic factor引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据